Humanigen Inc. (HGEN)
Stock Price:
$9.54 USD
0.58 (6.47%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $9.35 -0.19 (-1.99%) Nov 27, 4:02 PM
Key Info
| Market Cap |
492.42M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-59.27M |
| Shares Out |
51.62M |
| EPS (ttm) |
-2.00 |
| PE Ratio |
n/a |
| Forward PE |
2.19 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$9.54 |
| Previous Close |
$8.96 |
| Change ($) |
0.58 |
| Change (%) |
6.47% |
| Day's Open |
9.17 |
| Day's Range |
9.01 - 9.60 |
| Day's Volume |
340,749 |
| 52-Week Range |
1.50 - 33.95 |
More Stats
| Market Cap |
492.42M |
| Enterprise Value |
400.92M |
| Earnings Date (est) |
Mar 30, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
51.62M |
| Float |
41.26M |
| EPS (basic) |
-1.71 |
| EPS (diluted) |
-2.00 |
| FCF / Share |
-1.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
719,497 |
| Short Ratio |
1.74 |
| Short % of Float |
1.74% |
| Beta |
-0.78 |
| PE Ratio |
n/a |
| Forward PE |
2.19 |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
15.12 |
| Revenue |
n/a |
| Operating Income |
-57.58M |
| Net Income |
-59.27M |
| Free Cash Flow |
-46.71M |
| Net Cash |
91.50M |
| Net Cash / Share |
1.77 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-77.62% |
| ROE |
-183.48% |
| ROIC |
589.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$28.50*
(198.74% upside)
Low
25.0
Current: $9.54
High
34.0
Target: 28.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | 0.04 | 6.10 | 20.26 | 17.71 |
| Revenue Growth | - | - | - | - | - | - | -99.28% | -69.89% | 14.36% | - |
| Gross Profit | - | - | - | - | - | - | 0.04 | 6.10 | 20.26 | 17.71 |
| Operating Income | -8.94 | -11.48 | -19.03 | -27.01 | -34.35 | -36.72 | -40.91 | -23.48 | -2.27 | -6.12 |
| Net Income | -10.29 | -12.00 | -21.99 | -27.02 | -35.38 | -38.00 | -41.95 | -23.51 | -2.23 | -5.10 |
| Shares Outstanding | 22.36 | 18.95 | 3.00 | 1.94 | 0.83 | 0.82 | 0.61 | 0.05 | 0.05 | 0.04 |
| Earnings Per Share | -0.45 | -0.65 | -7.35 | -13.90 | -42.85 | -46.10 | -69.20 | -448.80 | -46.00 | -120.80 |
| Operating Cash Flow | -4.00 | -6.21 | -14.25 | -20.96 | -29.06 | -35.94 | -38.82 | -23.91 | -15.33 | 14.40 |
| Capital Expenditures | - | - | - | 0.01 | -0.02 | -0.45 | -0.34 | 0.15 | -0.46 | -0.07 |
| Free Cash Flow | -4.00 | -6.21 | -14.25 | -20.95 | -29.08 | -36.39 | -39.16 | -23.76 | -15.79 | 14.33 |
| Cash & Equivalents | 0.21 | 0.89 | 0.84 | 3.01 | 8.62 | 40.91 | 76.94 | 20.50 | 18.05 | 34.24 |
| Total Debt | 6.49 | 3.50 | 19.37 | 4.29 | 5.41 | 10.93 | 9.97 | 9.83 | - | - |
| Net Cash / Debt | -6.27 | -2.61 | -18.53 | -1.28 | 3.21 | 29.98 | 66.97 | 10.68 | 18.05 | 34.24 |
| Assets | 0.52 | 1.37 | 1.67 | 4.72 | 11.15 | 42.98 | 78.70 | 24.54 | 19.35 | 35.98 |
| Liabilities | 14.84 | 9.48 | 26.01 | 9.10 | 5.41 | 18.36 | 18.17 | 17.46 | 8.51 | 23.21 |
| Book Value | -14.32 | -8.11 | -24.34 | -4.38 | 5.73 | 24.61 | 60.54 | -94.94 | -72.35 | -70.40 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Humanigen Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Cameron Durrant |
Stock Information
| Ticker Symbol |
HGEN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: HGEN |
| IPO Date |
January 31, 2013 |
Description
Humanigen, a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.